PRESS RELEASES


Actavis Signs Option to Acquire Rhythm Subsidiary and its GI Development Product, Relamorelin
10/22/14

Rhythm Files Registration Statement for Proposed Initial Public Offering
08/27/14

Rhythm Presents Clinical Data that RM-493 Increases Energy Expenditure in Obesity Study
06/23/14

Rhythm Presents Positive Phase 2 Study Results for Ghrelin Prokinetic Relamorelin (RM-131) in Diabetic Gastroparesis
05/06/14

Rhythm Presents Positive GI Motility Results for Relamorelin (RM-131) in Phase 2 Chronic Constipation Study
05/06/14

Rhythm to Present at the Cowen and Company 34th Annual Health Care Conference
02/28/14

Rhythm Initiates Clinical Trial of RM-493 for Obesity Caused by Genetic Variant
09/24/13

Rhythm Awarded $1.35 Million from The Michael J. Fox Foundation to Advance Clinical Development of RM-131 for Refractory Constipation in Parkinson's Disease
09/10/13

Rhythm Announces Study Demonstrating High Prevalence of Diabetic Gastroparesis Symptoms in the U.S.
05/20/13

Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Gastroparesis in Patients with Type 1 Diabetes
05/20/13

Rhythm Initiates Phase 2 Clinical Trial of Ghrelin Prokinetic RM-131 for Lower GI Functional Disorders
04/16/13

Rhythm Initiates Phase 2 Clinical Trial of RM-493 for Obesity
01/04/13

Rhythm Expands Series B Financing to $33 Million; Adds Pfizer Ventures as an Investor
11/27/12

Rhythm Announces Positive Phase 1 Results for Ghrelin Prokinetic RM-131
10/22/12

Rhythm Raises $25M in Series B Financing for Diabetes and Obesity Therapeutics
06/13/12

Rhythm Initiates Phase 2 Clinical Trial of Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
06/06/12

Rhythm Announces Phase 1b Results for Ghrelin Prokinetic RM-131 for Diabetic Gastroparesis
05/22/12

Rhythm Names Lex Van der Ploeg Chief Scientific Officer
11/30/11

Rhythm Names Keith M. Gottesdiener Chief Executive Officer
11/09/11

Rhythm Expands Scientific Advisory Board for Clinical Programs in Metabolic Diseases
07/26/11

Rhythm's RM-131 Restores GI Function as a Potent Ghrelin Prokinetic
05/09/11

Rhythm Closes $40 Million Series A Financing
09/08/10

Rhythm's RM-493 Reverses Obesity and Insulin Resistance in Obese Primates
06/21/10

Rhythm Announces $21 Million Series A
03/15/10

Ipsen Grants Rhythm Exclusive Worldwide License for Two Programs in the Field of Metabolic Disorders
03/12/10